Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 18, 2019 - Issue 12
Submit an article Journal homepage
6,195
Views
10
CrossRef citations to date
0
Altmetric
Original Research

The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance

Kiyoshi AshidaDepartment of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto, JapanCorrespondence[email protected]
View further author information
,
Youichirou HondaJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, JapanView further author information
,
Katsuyuki SanadaPharmacovigilance Department, PRA Development Center KK, Osaka, JapanView further author information
,
Yukiko TakemuraJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, JapanView further author information
&
Shigeru SakamotoJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, JapanView further author information
Pages 1255-1261 | Received 18 Jun 2019, Accepted 02 Oct 2019, Published online: 24 Oct 2019

References

  • Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273–1275.
  • Eaton KA, Brooks CL, Morgan DR, et al. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun. 1991;59(7):2470–2475.
  • Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–490.
  • Bravo D, Hoare A, Soto C, et al. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018;24(28):3071–3089.
  • Guideline Committee of the Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Tokyo: Sentan Igaku Sha; 2016.
  • Kawai T, Takahashi S, Suzuki H, et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). J Gastroenterol Hepatol. 2014;29(Suppl. 4):29–32.
  • Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412–420.
  • Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori treatment: a lesson from Japan or a limited geographic phenomenon? Front Pharmacol. 2019;10:316.
  • Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects – a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719–730.
  • Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–1446.
  • Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240–251.
  • Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45(2):240–252.
  • Takara Y, Endo H, Nakano R, et al. Smoking and drinking did not increase the failure of therapeutic Helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin. Digestion. 2019;99(2):172–178.
  • Noda H, Noguchi S, Yoshimine T, et al. A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis. 2016;25(3):283–288.
  • Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97(3):212–218.
  • Sue S, Kuwashima H, Iwata Y, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med. 2017;56(11):1277–1285.
  • Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111(7):949–956.
  • Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39(1):5–12.
  • Gustavson LE, Kaiser JF, Edmonds AL, et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother. 1995;39(9):2078–2083.
  • Horikawa C, Kodama S, Fujihara K, et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106(1):81–87.
  • Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119(3):217–224.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.